Compare Ascendis Pharma A/S (ASND) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Warner Music Group Corp — how do they compare? Ascendis Pharma A/S trades at $263.91 (market cap $17.74B), while Warner Music Group Corp trades at $29.4 (market cap $15.12B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Warner Music Group Corp pays a 2.62% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WMG | |
|---|---|---|
Market Cap | $17.74B | $15.12B |
Sector | Health | Media |
52-Week High | $277.18 | $34.72 |
52-Week Low | $163.32 | $23.65 |
Enterprise Value | $18.11B | $19.32B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Warner Music Group (WMG) trades at $28.99, down 0.51% on the day, with a bullish technical signal driven by moving averages but mixed oscillators. The company reported revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Recent acquisitions like Sureel AI highlight strategic moves in AI-driven music attribution. Analyst consensus is strongly bullish with a $40.40 price target, implying significant upside from current levels.
WMG presents a compelling growth story with solid revenue expansion and strategic AI investments, but faces risks from margin compression and competitive pressures. The stock's high P/E of 34.51 suggests premium valuation, yet strong analyst buy ratings and institutional interest support further upside potential if execution on catalog monetization and streaming growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
